Stay updated with breaking news from Codexis daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stock analysts at Cantor Fitzgerald assumed coverage on shares of Codexis (NASDAQ:CDXS – Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $11.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 225.44% from the stock’s […] ....
Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Benchmark in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $9.00 target price on the biotechnology company’s stock. Benchmark’s target price suggests a potential upside of 129.59% from the stock’s current […] ....
Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have […] ....
Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned an average rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among […] ....
Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has received an average rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among […] ....